Exact Sciences (NASDAQ:EXAS - Get Free Report) announced its earnings results on Wednesday. The medical research company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.23, Zacks reports. The firm had revenue of $713.42 million for the quarter, compared to the consensus estimate of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 4.97%. Exact Sciences updated its FY 2025 guidance to EPS.
Exact Sciences Price Performance
Shares of NASDAQ EXAS traded down $0.25 during trading on Friday, reaching $49.26. The company had a trading volume of 3,339,540 shares, compared to its average volume of 2,338,169. Exact Sciences has a 52 week low of $40.62 and a 52 week high of $79.62. The stock has a market cap of $9.12 billion, a PE ratio of -8.84 and a beta of 1.24. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12. The business's 50 day moving average price is $54.91 and its 200-day moving average price is $59.99.
Analyst Ratings Changes
Several research firms have issued reports on EXAS. Stifel Nicolaus decreased their price target on shares of Exact Sciences from $82.00 to $67.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. Sanford C. Bernstein raised their price target on shares of Exact Sciences from $75.00 to $90.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Robert W. Baird decreased their price target on shares of Exact Sciences from $70.00 to $67.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 6th. Craig Hallum decreased their target price on shares of Exact Sciences from $82.00 to $65.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. Finally, Bank of America decreased their target price on shares of Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $72.06.
Check Out Our Latest Stock Report on Exact Sciences
About Exact Sciences
(
Get Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Read More
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
